Welcome to our dedicated page for NextPlat Equity Warrants Exp 29th Apr 2026 SEC filings (Ticker: NXPLW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NextPlat Corp (NXPLW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detail on topics such as governance decisions, shareholder votes, financial results announcements and listing matters related to the company’s common stock and warrants.
NextPlat’s recent Form 8-K filings describe events including the appointment of Rodney Barreto as Chairman of the Board and David Phipps as Chief Executive Officer following the passing of the prior Executive Chairman and CEO, as well as the announcement of quarterly financial results and the outcomes of its annual meeting of stockholders. One 8-K outlines shareholder voting results on the election of directors, ratification of the independent registered public accounting firm and advisory approval of executive compensation. Another 8-K discusses the company’s press release regarding financial results for a specific quarter.
Filings also document the company’s corporate information, such as its incorporation in Nevada and its listing on The Nasdaq Capital Market under the symbol NXPL, with related warrants referenced as NXPLW. In addition, NextPlat has publicly reported receiving an extension from Nasdaq to regain compliance with the minimum bid price requirement, a matter that may be further detailed in its regulatory communications.
On Stock Titan, these SEC filings are complemented by AI-powered summaries designed to explain the key points of each document in clear language. Users can review current reports, annual meeting voting results and other disclosures more efficiently, while still having access to the full original filings for deeper analysis.
NextPlat Corp is holding a virtual 2026 Annual Meeting of Stockholders on June 24, 2026 at 10:00 a.m. Eastern Daylight Time as a listen-only conference call and webcast. Holders of 2,708,507 shares of common stock as of April 27, 2026 may vote.
Stockholders will elect six directors, ratify RBSM LLP as independent auditor for 2026, approve on an advisory basis executive compensation, and authorize potential adjournment to solicit more proxies. The Board recommends voting “FOR” all director nominees and each proposal.
The Board has six members, four deemed independent under Nasdaq rules, with separate Audit, Compensation and Nominating Committees. Pay disclosures show 2025 total compensation of $652,980 for CEO David Phipps and $265,750 for CFO Amanda Ferrio, along with equity incentive plans and detailed severance terms.
NextPlat Corp is holding a virtual 2026 Annual Meeting of Stockholders on June 24, 2026 at 10:00 a.m. Eastern Daylight Time as a listen-only conference call and webcast. Holders of 2,708,507 shares of common stock as of April 27, 2026 may vote.
Stockholders will elect six directors, ratify RBSM LLP as independent auditor for 2026, approve on an advisory basis executive compensation, and authorize potential adjournment to solicit more proxies. The Board recommends voting “FOR” all director nominees and each proposal.
The Board has six members, four deemed independent under Nasdaq rules, with separate Audit, Compensation and Nominating Committees. Pay disclosures show 2025 total compensation of $652,980 for CEO David Phipps and $265,750 for CFO Amanda Ferrio, along with equity incentive plans and detailed severance terms.
NextPlat Corp shared preliminary expectations for its first quarter 2026 results, pointing to a continuing turnaround driven mainly by contracted healthcare services. The company expects Q1 2026 gross margins to rise to 34+% and operating expenses to decline by 8+% from Q4 2025.
First quarter consolidated gross profit is expected to increase by about 40% versus Q4 2025 as the business shifts toward higher-margin contracted healthcare revenue. NextPlat also reports a record number of added 340B entities, supporting anticipated healthcare services revenue growth and margin expansion through 2026, and is targeting positive operating income in the third quarter.
NextPlat Corp shared preliminary expectations for its first quarter 2026 results, pointing to a continuing turnaround driven mainly by contracted healthcare services. The company expects Q1 2026 gross margins to rise to 34+% and operating expenses to decline by 8+% from Q4 2025.
First quarter consolidated gross profit is expected to increase by about 40% versus Q4 2025 as the business shifts toward higher-margin contracted healthcare revenue. NextPlat also reports a record number of added 340B entities, supporting anticipated healthcare services revenue growth and margin expansion through 2026, and is targeting positive operating income in the third quarter.
NextPlat Corp has regained compliance with Nasdaq’s minimum bid price rules, removing a prior delisting risk. The company had previously been notified that its stock traded below $1.00 for 30 straight trading days, triggering a grace period to cure the deficiency.
Nasdaq later confirmed that, for the 10 consecutive business days from April 13, 2026 to April 24, 2026, NextPlat’s closing bid price was at or above $1.00 per share. As a result, Nasdaq issued a compliance letter on April 27, 2026, closed the matter, and NextPlat remains listed on The Nasdaq Capital Market under the ticker “NXPL”.
NextPlat Corp has regained compliance with Nasdaq’s minimum bid price rules, removing a prior delisting risk. The company had previously been notified that its stock traded below $1.00 for 30 straight trading days, triggering a grace period to cure the deficiency.
Nasdaq later confirmed that, for the 10 consecutive business days from April 13, 2026 to April 24, 2026, NextPlat’s closing bid price was at or above $1.00 per share. As a result, Nasdaq issued a compliance letter on April 27, 2026, closed the matter, and NextPlat remains listed on The Nasdaq Capital Market under the ticker “NXPL”.
NextPlat Corp director Anthony Armas, through Apollo Two MSO, LLC, reported an indirect acquisition of Common Stock as a compensation-related grant. The entity received 12,162 shares of NextPlat Common Stock at a stated price of $0.00 per share, characterized as a grant or award.
Following this transaction, Apollo Two MSO, LLC’s indirect holdings associated with Armas increased to 113,316 shares of Common Stock. The filing reflects a non-market, award-type acquisition rather than an open-market purchase or sale.
NextPlat Corp director Anthony Armas, through Apollo Two MSO, LLC, reported an indirect acquisition of Common Stock as a compensation-related grant. The entity received 12,162 shares of NextPlat Common Stock at a stated price of $0.00 per share, characterized as a grant or award.
Following this transaction, Apollo Two MSO, LLC’s indirect holdings associated with Armas increased to 113,316 shares of Common Stock. The filing reflects a non-market, award-type acquisition rather than an open-market purchase or sale.
NextPlat Corp director Rodney Barreto received a stock grant that increased his direct ownership. On April 6, 2026, he was awarded 24,324 shares of NextPlat common stock at no stated purchase price. After this grant, his direct holdings rose to 469,909 common shares, reflecting a routine compensation-related acquisition rather than an open-market purchase.
NextPlat Corp director Rodney Barreto received a stock grant that increased his direct ownership. On April 6, 2026, he was awarded 24,324 shares of NextPlat common stock at no stated purchase price. After this grant, his direct holdings rose to 469,909 common shares, reflecting a routine compensation-related acquisition rather than an open-market purchase.
ELLENOFF DOUGLAS reported acquisition or exercise transactions in this Form 4 filing.
NextPlat Corp director Douglas Ellenoff received a grant of 24,324 shares of NextPlat common stock on April 6, 2026. The shares were awarded at no cash cost per share, reflecting equity compensation rather than an open‑market purchase. Following this award, Ellenoff directly owns 190,500 NextPlat common shares.
ELLENOFF DOUGLAS reported acquisition or exercise transactions in this Form 4 filing.
NextPlat Corp director Douglas Ellenoff received a grant of 24,324 shares of NextPlat common stock on April 6, 2026. The shares were awarded at no cash cost per share, reflecting equity compensation rather than an open‑market purchase. Following this award, Ellenoff directly owns 190,500 NextPlat common shares.
NextPlat Corp is implementing a 1-for-10 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on April 13, 2026. Every 10 existing shares will be combined into 1 share, with par value staying at $0.0001.
The reverse split will reduce outstanding common shares from approximately 26.9 million to approximately 2.7 million, while authorized shares remain at 50 million. Stock options, warrants and equity plan reserves will be adjusted proportionately, increasing exercise prices and reducing underlying share amounts. No fractional shares will be issued; instead, holders will receive cash based on the Nasdaq closing price on the effective date.
NextPlat’s stock is expected to begin trading on a split-adjusted basis on April 13, 2026 under the symbol “NXPL” with a new CUSIP number. Historical per-share figures, including net loss per share, have been recast to reflect the new share count for 2025 and 2024.
NextPlat Corp is implementing a 1-for-10 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on April 13, 2026. Every 10 existing shares will be combined into 1 share, with par value staying at $0.0001.
The reverse split will reduce outstanding common shares from approximately 26.9 million to approximately 2.7 million, while authorized shares remain at 50 million. Stock options, warrants and equity plan reserves will be adjusted proportionately, increasing exercise prices and reducing underlying share amounts. No fractional shares will be issued; instead, holders will receive cash based on the Nasdaq closing price on the effective date.
NextPlat’s stock is expected to begin trading on a split-adjusted basis on April 13, 2026 under the symbol “NXPL” with a new CUSIP number. Historical per-share figures, including net loss per share, have been recast to reflect the new share count for 2025 and 2024.
NextPlat Corp reported full-year 2025 revenue of approximately $54.3 million, down 18% from about $66.1 million in 2024, as healthcare prescription volumes declined but e-commerce grew modestly. Healthcare revenue fell to $39.7 million from $52.3 million, driven by fewer prescriptions and lower 340B contract revenue, partly offset by higher reimbursement per script.
e-Commerce revenue increased to $14.6 million from $13.8 million on stronger airtime and hardware sales and favorable foreign exchange. Overall gross margin declined to about 20% from 26%, but total operating expenses were cut roughly in half to $19.9 million from $40.0 million, reflecting cost reductions and the absence of a prior-year impairment loss. Net loss attributable to common stockholders narrowed to approximately $11.7 million, or $0.44 per share, from $13.4 million, or $0.65 per share. The company ended 2025 with about $13.7 million in cash and roughly $15.0 million in working capital.
NextPlat Corp reported full-year 2025 revenue of approximately $54.3 million, down 18% from about $66.1 million in 2024, as healthcare prescription volumes declined but e-commerce grew modestly. Healthcare revenue fell to $39.7 million from $52.3 million, driven by fewer prescriptions and lower 340B contract revenue, partly offset by higher reimbursement per script.
e-Commerce revenue increased to $14.6 million from $13.8 million on stronger airtime and hardware sales and favorable foreign exchange. Overall gross margin declined to about 20% from 26%, but total operating expenses were cut roughly in half to $19.9 million from $40.0 million, reflecting cost reductions and the absence of a prior-year impairment loss. Net loss attributable to common stockholders narrowed to approximately $11.7 million, or $0.44 per share, from $13.4 million, or $0.65 per share. The company ended 2025 with about $13.7 million in cash and roughly $15.0 million in working capital.
NextPlat Corp is a Nevada-based global e-commerce and healthcare services company operating two segments: e-Commerce Operations and Healthcare Operations. For the year ended December 31, 2025, approximately 27% of revenue came from e-Commerce and 73% from healthcare.
The e-Commerce segment sells satellite communications equipment and recurring airtime services through three proprietary websites, about 25 third-party storefronts and more than 10,000 product listings, reaching customers in over 165 countries. Amazon marketplaces represented approximately 31% of e-Commerce revenue in 2025.
The healthcare segment operates Progressive Care’s Pharmco pharmacies and ClearMetrX, providing retail and long-term care pharmacy services, 340B contract pharmacy services, data analytics and medication management in Florida and multiple other states. A Five Star EQuIPP performance score in 2025 highlights strong adherence metrics.
The company remains loss-making, with net losses of approximately $10.5 million in 2025 and $22.5 million in 2024 and an accumulated deficit of about $60.1 million as of December 31, 2025. As of March 27, 2026, there were 27,026,215 common shares outstanding, and non-affiliate equity was valued at about $11.2 million as of June 30, 2025.
NextPlat faces significant risks, including reliance on Amazon for e-commerce sales, dependence on McKesson for about 98% of pharmaceutical purchases in 2025, heavy use of the 340B Drug Pricing Program, and extensive healthcare and data privacy regulation. The company has received Nasdaq notices for failing to meet the $1.00 minimum bid price and pursued a 1-for-10 reverse stock split approved on March 27, 2026 to regain compliance and avoid potential delisting.
NextPlat Corp is a Nevada-based global e-commerce and healthcare services company operating two segments: e-Commerce Operations and Healthcare Operations. For the year ended December 31, 2025, approximately 27% of revenue came from e-Commerce and 73% from healthcare.
The e-Commerce segment sells satellite communications equipment and recurring airtime services through three proprietary websites, about 25 third-party storefronts and more than 10,000 product listings, reaching customers in over 165 countries. Amazon marketplaces represented approximately 31% of e-Commerce revenue in 2025.
The healthcare segment operates Progressive Care’s Pharmco pharmacies and ClearMetrX, providing retail and long-term care pharmacy services, 340B contract pharmacy services, data analytics and medication management in Florida and multiple other states. A Five Star EQuIPP performance score in 2025 highlights strong adherence metrics.
The company remains loss-making, with net losses of approximately $10.5 million in 2025 and $22.5 million in 2024 and an accumulated deficit of about $60.1 million as of December 31, 2025. As of March 27, 2026, there were 27,026,215 common shares outstanding, and non-affiliate equity was valued at about $11.2 million as of June 30, 2025.
NextPlat faces significant risks, including reliance on Amazon for e-commerce sales, dependence on McKesson for about 98% of pharmaceutical purchases in 2025, heavy use of the 340B Drug Pricing Program, and extensive healthcare and data privacy regulation. The company has received Nasdaq notices for failing to meet the $1.00 minimum bid price and pursued a 1-for-10 reverse stock split approved on March 27, 2026 to regain compliance and avoid potential delisting.
NextPlat Corp reported that on September 3, 2025 its Board appointed Rodney Barreto as Chairman and David Phipps as Chief Executive Officer, converting each from their interim roles following the May 2025 death of former Executive Chairman and CEO Charles M. Fernandez. Mr. Barreto had served as Interim Chairman and Mr. Phipps had served as Interim Chief Executive Officer since May.
The company states that Mr. Phipps’s existing employment agreement remains unchanged at the time of his permanent appointment. The company issued a press release on September 9, 2025 announcing the appointments and filed that release as Exhibit 99.1 to this Current Report.